Showing results (11-20 of 3,331) with videos related to
Sort By:
Pageof 334
Pharmacoeconomics|March 12, 2016
Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT TrialLars Oddershede, Simon Walker, Wolfgang Stöhr, et al.Pharmacoeconomics|March 27, 2013
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statementDon Husereau, Michael Drummond, Stavros Petrou, et al.Pharmacoeconomics|March 27, 2013
A systematic review of utility values for chemotherapy-related adverse eventsFatiha H Shabaruddin, Li-Chia Chen, Rachel A Elliott, et al.Pharmacoeconomics|March 21, 2013
Using a discrete choice experiment to elicit time trade-off and willingness-to-pay amounts for influenza health-related quality of life at different agesLisa A Prosser, Katherine Payne, Donna Rusinak, et al.Pharmacoeconomics|January 8, 2016
Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling StudyKathryn Coyle, Doug Coyle, Julie Blouin, et al.Pharmacoeconomics|January 22, 2016
Biosimilars: How Can Payers Get Long-Term Savings?Jorge Mestre-Ferrandiz, Adrian Towse, Mikel BerdudPharmacoeconomics|December 31, 2015
Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life CareJoanna Coast, Elisabeth Huynh, Philip Kinghorn, et al.Pharmacoeconomics|December 31, 2015
Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?Beth Woods, Rita Faria, Susan GriffinPharmacoeconomics|February 11, 2016
Identification of Evidence for Key Parameters in Decision-Analytic Models of Cost Effectiveness: A Description of Sources and a Recommended Minimum Search RequirementSuzy PaisleyPharmacoeconomics|June 3, 2016
Sustainable Financing of Innovative Therapies: A Review of ApproachesAidan HollisPageof 334